Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Eixos temáticos
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Clin Neuropharmacol ; 45(6): 162-167, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-36383914

RESUMO

INTRODUCTION: Lomustine is regarded as 1 common anti-vascular endothelial growth factor agent. The efficacy of adjuvant lomustine to chemotherapy remains controversial for recurrent glioblastoma. We conduct this meta-analysis to explore the influence of adjuvant lomustine on treatment efficacy of recurrent glioblastoma. METHODS: We have searched PubMed, EMBASE, Web of Science, EBSCO, and Cochrane library databases through August 2019 and included randomized controlled trials assessing the efficacy and safety of adjuvant lomustine for recurrent glioblastoma. RESULTS: Four randomized controlled trials are included in the meta-analysis. Overall, compared with the control group for recurrent glioblastoma, adjuvant lomustine has no substantial effect on objective response (risk ratio [RR], 1.32; 95% confidence interval [CI], 0.91 to 1.93; P = 0.15), complete response (RR, 1.76; 95% CI, 0.26-11.90; P = 0.56), progressive response (RR, 1.32; 95% CI, 0.88-1.99; P = 0.18), median progression-free survival (standard mean difference [SMD], 0.73; 95% CI, -0.65 to 2.11; P = 0.30), or median overall survival (SMD, 0.26; 95% CI, -0.30-0.83; P = 0.36), but results in the increase in 6-month progression-free survival (SMD, 1.71; 95% CI, 0.38-3.04; P = 0.01). There is no increase in grade ≥3 adverse events after adjuvant lomustine treatment (RR, 1.55; 95% CI, 0.84-2.89; P = 0.16) compared with control intervention. CONCLUSIONS: Adjuvant lomustine to other chemotherapy may provide no obvious benefits for the treatment of recurrent glioblastoma.


Assuntos
Neoplasias Encefálicas , Glioblastoma , Lomustina , Recidiva Local de Neoplasia , Humanos , Neoplasias Encefálicas/tratamento farmacológico , Glioblastoma/tratamento farmacológico , Lomustina/efeitos adversos , Recidiva Local de Neoplasia/tratamento farmacológico , Ensaios Clínicos Controlados Aleatórios como Assunto , Resultado do Tratamento
2.
J Mol Histol ; 52(3): 589-596, 2021 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-33725213

RESUMO

Glioblastoma (GBM) is a deadly brain tumor with a bleak prognosis. In recent years, the copine III (CPNE3) protein was discovered to be associated to metastasis across various types of malignancies. Nevertheless, its function has not been well documented in glioma. This study characterizes CPNE3 expression in GBM along with its impact and underlying molecular mechanism with regards to cellular migration, invasion and proliferation. Immunohistochemistry was used to characterizes CPNE3 expression in the glioma tissues. Then, knockdown of CPNE3 expression was used to analyze the role of CPNE3 in GBM cell viability, migration, invasion. Western blot analysis was performed to measure the protein levels of FAK signaling pathway. We found that GBM tissues had higher CPNE3 expressions as compared to those in normal brain tissues. CPNE3 silencing in GBM cells impaired the migratory, invasive and proliferative abilities of GBM cells that can be attributed to inactivation of the FAK signaling pathway. Collectively, these findings highlight the role of CPNE3 as a new biomarker, offering deeper insights into its carcinogenic role in GBM.


Assuntos
Neoplasias Encefálicas/patologia , Movimento Celular/genética , Proteína-Tirosina Quinases de Adesão Focal/metabolismo , Glioblastoma/genética , Glioblastoma/patologia , Fosfoproteínas/genética , Transdução de Sinais , Regulação para Cima/genética , Animais , Neoplasias Encefálicas/genética , Linhagem Celular Tumoral , Proliferação de Células/genética , Regulação Neoplásica da Expressão Gênica , Inativação Gênica , Humanos , Camundongos Nus , Invasividade Neoplásica , Fosfoproteínas/metabolismo , RNA Interferente Pequeno/metabolismo
3.
Chinese Journal of School Health ; (12): 1692-1697, 2021.
Artigo em Chinês | WPRIM | ID: wpr-906566

RESUMO

Objective@#To summarize the effective of high intensity interval training on cognitive executive function among adolescents through Meta analysis,and to provide reference for medical rehabilitation and physical education practice.@*Methods@#Literature search was conducted for Chinese and English keywords "High Intensity Interval Training", "Cognition", "Cognition Function","Executive Function" and "Executive Controls" regarding the effect of high intensity interval training on cognitive executive function among adolescents published prior to September 20, 2020 in PubMed, Cochrane library, Web of science, Embase, the China National Knowledge Infrastructure (CNKI), the Wanfang database and the VIP database. Stata 14 software and Revman 5.3 software were used for Meta analysis, fixed effect or random effect model was used to combine the results based on the heterogeneity.@*Results@#The response time of Stroop test immediately after acute high intensity interval training significantly decreased ( SMD=0.70,95%CI =0.28-1.11, z=3.29,P <0.01); there was no significant change in response time of Stroop test 30 min after training ( SMD=0.23,95%CI=-0.14-0.60,z=1.23,P >0.05); the correct rate of Stroop test immediately after acute high intensity interval training increased significantly ( SMD=0.26,95%CI=0.03-0.50,z=2.21,P <0.05); there was no significant change in correct rate of Stroop test 30 min after training ( SMD=-1.38,95%CI=-4.28-1.52,z=0.93,P >0.05). After long term high intensity interval training, the response time of Stroop and TMT test were significantly shortened ( SMD=0.38, 95%CI=0.07-0.70, z=2.41, P < 0.05 ).@*Conclusion@#Acute and long term high intensity interval training can effectively improve cognitive executive function among adolescents, but the long term effect of acute training is unclear.

SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa